Due to a system-wide technology update, we are experiencing extremely high call volume. We appreciate your patience with our operators during this time. Thank you for choosing Fox Chase Cancer Center.
Cancer Therapeutics and Discovery Targets
Technology Transfer Contacts
- Inna Khartchenko, MS, MBA
Director, Technology Transfer
215-214-3989
Inna.Khartchenko@fccc.edu - Natalia Shalginskikh, PhD
Licensing Associate,
Technology Transfer
267-963-7121
Natalia.Shalginskikh@fccc.edu - Tatiana Venkova, PhD
Licensing Associate,
Technology Transfer
215-983-0257
Tatiana.Venkova@fccc.edu
(technologies available for licensing)
Note: Links to Patents may require a browser newer than Internet Explorer 9, such as Chrome, Safari, Firefox, Edge, or Internet Explorer 11|
TECH ID |
TITLE |
LEAD INVENTOR |
CONTACT |
|---|---|---|---|
|
02-15 |
ATR kinase: a novel cellular target for anti- retroviral drug discovery and therapy |
Anna Marie Skalka |
|
|
03-13 |
Targeted therapy for ovarian cancer: Anti-Mullerian Inhibiting Substance Type II Receptor (MISIIR) Immunoconjugates to Detect and Treat Cancer |
Gregory Adams |
|
|
06-16 |
Treatment of diseases associated with aberrant ciliary function |
Erica Golemis |
|
|
07-05 |
Compositions and Methods for Altering Pancreas and Liver Functions |
Kenneth Zaret |
|
|
07-29 |
Secreted/cell bound poxvirus proteins and methods of use thereof as vaccines and antiviral agents |
Luis Sigal |
|
|
07-40 |
EFGR/NEDD9/TGF-β Interactome and Methods for the Identification of Agents for the Treatment of Hyperproliferative Disorders |
Igor Astsaturov |
|
|
104-JT |
Methods to Treat Hepatitis B and other Liver Disorders |
John Taylor |
|
|
108-YM |
Synergistic Cytotoxic Effects of 5-Fluorouracil Derivatives and 5-Hydroxymethyluracil Derivatives |
Yoshihiro Matsumoto |
|
|
114-EH |
Method for the Treatment of Lymphangioleiomyomatosis (LAM) |
Elizabeth Henske |
|
|
115-IR |
Use of Synthetic Peptides for the Prevention and Treatment of Breast Cancer |
Irma Russo |
|
|
151-EG |
Combination Therapy for the Treatment of Cancer: Aurora A Kinase Inhibitors and Dasatinib |
Erica Golemis |
|
|
196-MM |
Modulators of Hsp70/ Dnak Function |
Maureen Murphy |
|
|
222-HB |
A Highly Specific Antibody Targeting Tumor Endothelial Marker 7R |
Hossein Borghaei |
|
|
243-MC |
Targeting of Cytochrome CYP1B1 in the Treatment of Head and Neck and Lung Cancers |
Margie Clapper |
|
|
250-MA |
New Drug Target Site of HIV Integrase for AIDS Therapy |
Mark Andrake |
|
|
264-JP |
Small Molecule Inhibitors of ACK1 for Treating Cancer and Dyskinesia in Parkinson’s Disease |
Jeffrey Peterson |
|
|
276-GA |
Rationally-designed Anti-Mullerian Inhibiting Substance Type II Receptor Antibodies |
Gregory Adams |
|
|
280-TY |
Combination Inhibition of the Vitamin D Receptor and DNA Replication in the Treatment of Cancer |
Timothy Yen |
|
|
311-AB |
Combination of DNA Repair Inhibition With Bendamustine or Gemcitabine in the Treatment of Cancer |
Alfonso Bellacosa |
|
|
314-VK |
New Anticancer Zinc Chetatin Agents for Therapy of Advanced Prostate Cancer |
Vladimir Kolenko |
|
|
326-NB |
Sensitization of Cancer Cells to DNA Damage by Inhibiting Kinases Essential for DNA Damage Checkpoint Control |
Timothy Yen |
|
|
337-ZY |
Novel Treatment of Medulloblastoma by Inhibition of Leukotriene Synthesis and Activity |
Zeng-Jie Yang |
|
|
346-AB |
Novel Methods for Inhibiting Growth and Proliferation of Melanoma Cells |
Alfonso Bellacosa |
|
|
349-IA |
C-MYC as a Novel Biomarker of Cancer Therapeutic Efficacy |
Igor Astsaturov |
|
|
370-AT |
Novel Class of PARP-1 Blockers for the Treatment of Prostate and Renal Cancers |
Alexei Tulin |
|
|
381-TY |
Combined Inhibition of the Vitamin D Receptor and Poly (ADP) Ribose Polymerase-1 (PARP-1) in Cancer Therapy |
Timothy Yen |
|
|
394-EG |
Systems and Methods for Treating Patients Having a Genetic Predisposition to Develop Prostate Cancer Published Application No.WO2017049023A1; Summary Other Patent Applications Pending |
Erica Golemis |
|
|
404-WE |
Prodigiosin Analogs as Cancer Therapeutics |
Wafik El-Deiry |
|
|
407-SB |
Viral-Based Cancer Gene Therapy and Treatment of Influenza Infection Through Induction of Cell Death |
Siddharth Balachandran |
|
|
424-WE |
MicroRNA as Targeting CDK4/6-Cell Cycle Pathways Treatment for Cancer |
Wafik El-Deiry |
|
|
425-MA |
Small Molecule Allosteric Inhibitors of HIV Integrase |
Mark Andrake |
|
|
426-SA |
Methods For Diagnosis And Treatment Of Patients Having Solid Tumors |
Sanjeevani Arora |
|
|
427-ZY |
Cholesterol Synthesis Inhibitors Synergize with Smoothened Antagonist for Treatment of Hedgehog Pathway Malignancies |
Zeng-Jie Yang |
|
|
429-RD |
Chimera of Bone Morphogenic Protein 2 and the Mullerian Inhibiting Substance Type II Receptor Binding Region of Mullerian Inhibiting Substance |
Roland Dunbrack |
|
|
430-WE |
Compounds For Repressing Cancer Cell Growth |
Wafik El-Deiry |
|
|
431-WE |
High EGFR Somatic Mutation Frequency Targeting the TK Domain in Colorectal Cancer Patients with Microsatellite Instability (MSI) |
Wafik El-Deiry |
|
|
432-WE |
Dual Inhibition of CDK1 and HSP90 Destabilize HIF1a and Synergistically Induces Cancer Cell Death |
Wafik El-Deiry |
|
|
438-JD |
Generating a Kinome Profile for Cancer Therapy |
James Duncan |
|
|
439-EC |
Pancreatic Cancer Associated Desmoplastic Immune Checkpoint Inhibitor |
Edna Cukierman |
|
|
441-JR |
Development of a Panel of Markers Predicting Response of Breast Cancer Prevention |
Jose Russo |
|
|
447-WE |
TRAIL Upregulating miRNA with Apoptotic Activity |
Wafik El-Deiry |
|
|
461-PA |
Urinary DNA Detection for Monitoring of Urothelial Cancer |
Philip Abbosh |
|
|
462-PM |
Combination of Sunitinib with Farnesyl-Transferase Inhibitors as a Next Generation Therapeutic Approach |
Petr Makhov |
|
|
469-ME |
Radiotherapeutic Combination Therapy For Treatment of Cancer |
Martin Edelman |
|
|
477-DC |
A novel antibody for the treatment of ovarian and other cancers |
Denise Connolly |
|
|
482-SB |
Protein Kinase Inhibitors and Uses Thereof for the Treatment of Diseases and Conditions |
Siddharth Balachandran |
|
|
484-EC |
Reagent/Drug(s) to Prevent NetricGI/NGLI Engagement |
Edna Cukierman |
|
|
485-JK |
Using Chemical Biology to Enable Precision Immuno-Oncology |
John Karanicolas |
|
|
493-LW |
Methods of Inhibiting Proliferation of Estrogen-Independent Cancer Cells |
Louis Weiner |
|
|
494-AP |
Novel Druggable Targets on the Interface of Oncogenic and Metabolic Pathways |
Andrzej Ptasznik |
|
|
498-PA |
Azolium Salts for Treatment of Non-Muscle Invasive Bladder Cancer |
Philip Abbosh |
|
|
499-JD |
Combination Therapy for Treatment of Cancer (PROTACs and mTORC inhibitors) |
James Duncan |
|
|
520-AB |
TDG inhibitors for the treatment of cancer and other diseases |
Alfonso Bellacosa |
|
|
522-MC |
Estrogen Metabolite Levels and EGFR Mutations in Lung Cancer Risk Stratification and Treatment |
Margie Clapper |
|
|
534-JR |
Treatment of females having BRCA1/2 mutations with human chorionic gonadotropin to reduce the risk of developing breast cancer |
Jose Russo |
|
|
536-EK |
Treatment Of Non-Alcoholic Steatohepatitis (NASH) With IL-27 Antibody |
Ekaterina Koltsova |
|
|
541-JW |
Treatment of Integrin-Related Disorders With Stapled Peptides |
Jinhua Wu |
|
|
543-JRW |
Compositions And Methods For Regulating EGFR Amplification In Cancer Cells For Improving Efficacy Of EGFR-Targeted Anti-Cancer Agents
|
Johnathan R Whetstine
|
|
|
544-JK |
Compositions and Methods for Modulation of Antibody Activity Patent Pending; Summary in 485-JK. |
John Karanicolas |
|
|
546-JT |
Malignant Mesothelioma Susceptibility as a Result of Germline Gene Alteration Patent Pending; Summary |
Joseph Testa |
|
|
550-PA |
Personalized therapeutic cancer vaccines based on aberrantly translated introns for patients with tumors harboring Patent Pending; Summary |
Philip Abbosh |
|
|
552-JD |
Combining ABCB1 inhibitors with PROTAC therapies to improve therapeutic responses Patent Pending; Summary |
James Duncan |
|
| 554-JC |
Novel PAK1-Selective Degrader for Treatment of Cancer Patent Pending |
Jonathan Chernoff | Tatiana Venkova |
|
563-IA |
TMEM16F is the key regulator of trogocytosis in cancer-associated fibroblasts and is a target for the existing anti-helminthic drugs. Patent Pending |
Igor Astsaturov |
|
|
567-ZY |
Thyroid hormone treats medulloblastoma Patent Pending |
Zeng-Jie Yang |
Share
-
Share with Facebook
-
Share with twitter
-
Share with email
-
Print this